Phyxius Pharma, Inc. Information

Phyxius Pharma, Inc. is a privately held specialty pharmaceutical company focused on developing and commercializing critical care pharmaceutical products in North America. Our business strategy is to create patient and shareholder value by leveraging our pharmaceutical development and commercialization expertise to bring innovative critical care therapeutics to the market. The Phyxius Pharma management team has over 95 years of collective pharmaceutical experience, including senior executive level positions in general management, operations, commercial, and regulatory. This experience spans multiple acute care and cardiovascular brands, as well as significant clinical trial management and pharmacoeconomic experience. In addition, our significant experience in the critical care market provides the company with unique relationships with many thought leaders. The company recently acquired the North American (US and Canada) rights to develop and commercialize Simdax (levosimendan) from Orion Corporation of Finland. Our immediate focus is on the development of levosimendan for the prevention of low cardiac output syndrome (LCOS). We expect to add other critical care products to our portfolio in the future.